Oracea (doxycycline generic, CollaGenex) has been approved for the treatment of inflammatory lesions in adults with rosacea, a dermatological condition. This is the first FDA-approved, orally administered, systemically delivered drug to treat rosacea. This 40-mg capsule offers the convenience of once-a-day administration and contains a combination of immediate-release and delayed-release beads. Rosacea primarily affects the [...]
The Food and Drug Administration (FDA) has approved the first generic version of generic metronidazole vaginal gel (MetroGel, QLT USA), a treatment for bacterial vaginosis. This infection is characterized by vaginal discharge, and it results from an overgrowth of bacteria in the vagina.
The FDA has alerted prescribers of new safety concerns about linezolid (Zyvox generic, Pfizer). A recent open-label, randomized trial compared linezolid with vancomycin (Vancocin, Viro Pharma), oxacillin (Bactocill, SmithKlineBeecham; Prostaphlin, Apothecon), or dicloxacillin (Dycill, GlaxoSmithKline; Dynapen, Apothecon) in seriously ill patients with intravascular catheter-related bloodstream and catheter-site infections. Patients receiving linezolid had a higher chance [...]
Retapamulin ointment (Altabax, Glaxo-SmithKline) has been approved for the topical treatment of impetigo caused by susceptible strains of Staphylococcus aureus or Streptococcus pyogenes, the two most common types of bacteria in this kind of infection. Impetigo is considered a contagious infection of the skin’s top layers. It is most common among infants and children two [...]
This study presented at the International Society of quality of Life demonstrated that children taking Omnicef drug were 28 percent more likely to finish all their medication than those taking Augmentin antibiotic. Parents regarded generic Omnicef a significantly effective, easier-to-use medicine in the antibiotic list to treat acute otitis media. In this study, researchers compared [...]
Oral antibiotic omnicef (cefdinir) is indicated for pediatric patients (ages six months to 12 years) in the form of suspension to treat from mild to moderate infections: acute bacterial otitis media, Haemophilus influenzae (including beta-lactamase-producing strains), Streptococcus pneumoniae (penicillin-susceptible strains only) and Moraxella catarrhalis (including beta-lactamase-producing strains); and pharyngitis/tonsillitis due to Streptococcus pyogenes. Generic Omnicef [...]
Abbott Laboratories announced today that a new FDA approved 250mg/5m dosing option of the antibiotic Omnicef (generic cefdinir) Oral Suspension (OS) is available for use in pediatric patients six months to 12 years old. The more concentrated 250mg/5mL formulation allows parents to administer fewer teaspoons per dose of the antibiotic to their children. When using [...]
